The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA (clesrovimab-cfor) , a ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

The U.S. Food and Drug Administration has approved Merck's Enflonsia, a treatment to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The company said ...

Cleveland health officials are warning residents after a 250% spike in COVID-19 viral levels was found in city wastewater.

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.